2 recruiting, 1 not yet recruiting, 1 withdrawn. 2 Phase 1, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 1, Withdrawn 1 |
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow HR Positive: new trials by email Literature Review of HR Positive trials Research Report on HR Positive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd Trastuzumab deruxtecan, Trastuzumab, Pertuzumab - Advanced Breast Cancer, Metastatic Breast Cancer | Phase 3 | Recruiting | Daiichi Sankyo | 200 | 2026-09-18 | 2026-10-16 |
| Pragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Oncotype DX and Abemaciclib Abemaciclib - Breast Cancer, HER2 + Breast Cancer | Phase 2 | Not yet recruiting | Mario Negri Institute for Pharmacological Research | 150 | 2026-04-30 | 2026-03-05 |
| PRE-ISPY Phase I/II Oncology Platform Program ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab - HER2-positive Breast Cancer, Metastatic Cancer | Phase 1 / Phase 2 | Recruiting | QuantumLeap Healthcare Collaborative | 280 | 2023-02-15 | 2026-09-30 |
| ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer Vic-trastuzumab duocarmazine (SYD985) + paclitaxel - HER2-positive Breast Cancer, HER2 Low | Phase 1 | Withdrawn | QuantumLeap Healthcare Collaborative | 2021-07-28 | 2023-11-18 |
Breast Neoplasms (4) · Neoplasm Metastasis (2) · Triple Negative Breast Neoplasms (2) · Adenocarcinoma (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Neoplasm, Residual (1) · Ovarian Neoplasms (1) · Rectal Neoplasms (1) · Urinary Bladder Neoplasms (1)
Breast Diseases (4) · Neoplasms (4) · Neoplasms by Site (4) · Skin Diseases (4) · Skin and Connective Tissue Diseases (4) · Neoplastic Processes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Adnexal Diseases (1) · Carcinoma (1) · Colonic Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1)
ALX148 (1) · Paclitaxel (1) · Trastuzumab (1) · abemaciclib (1) · palbociclib (1) · pertuzumab (1) · trastuzumab deruxtecan (1) · trastuzumab duocarmazine (1) · tucatinib (1) · zanidatamab (1)
QuantumLeap Healthcare Collaborative (2) · Daiichi Sankyo (1) · Mario Negri Institute for Pharmacological Research (1)
United States (3) · Italy (1)